Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Comment by thegoldfishon Feb 14, 2012 2:17pm
243 Views
Post# 19532759

RE: RE: RE: RE: RE: RE: NI43-101 UPDATE?

RE: RE: RE: RE: RE: RE: NI43-101 UPDATE?

The problem, one I am all too familiar with regarding another holding of mine, Evolving Gold, is setting up target dates and not hitting them.

It's an open invitation for speculation when the time comes and goes without the promised results. If you aren't sure you can hit a target, don't give one. Don't put out that you expect things by the end of a month, then say nothing when you miss the target. Put out a news release with an explanation, for crying out loud.

In the case of Evolving Gold, delays and missed targets often were bad news. I hope I haven't jinxed you long-term GPD holders by buying in here a couple of months back!

Bullboard Posts